Operating signal within 12 months from two or more independent sources.
What they make
Surgical and Medical Instrument Manufacturing339112Alcresta Therapeutics develops enzyme-based products for rare diseases, specifically addressing fat malabsorption in patients requiring enteral nutrition. The company's product RELiZORB contains iLipase, a patented microbead/enzyme technology designed to break down fat for absorption in patients who are enterally fed at home or in the hospital, often those with exocrine pancreatic insufficiency.
SUMMARIZED FROM THE COMPANY’S OWN WEBSITE
Products
Where these came from
Where it is
Location not verified — this address could not be matched to Census TIGER, so the facility is not placed on the map.
Other plants nearby
No other listed facility within 40 km shares this one’s four-digit industry code, or this record has no coordinates to measure from.
Also at this address
No other federal record shares this street address.
WHERE THIS RECORD COMES FROM — 3 FEDERAL SOURCES, 7 FIELDS
Every fact on this page traces to a public federal filing. The table below names which register holds this facility, whether that register proves the plant operates or only that it exists, and when each of them last saw it.
| Source | Evidence | First seen | Last seen |
|---|---|---|---|
| FDA DEVICES | OPERATING | AUG 2026 | AUG 2026 |
| COMPANY SITE | OPERATING | JUL 2026 | AUG 2026 |
| SAM GOV | OPERATING | OCT 2025 | OCT 2025 |
FIELD BY FIELD — WHICH SOURCE SUPPLIED WHAT
| FIELD | SOURCE | SIGNAL |
|---|---|---|
| ADDRESS LINE1 | SAM GOV | OCT 2025 |
| CAGE CODE | SAM GOV | OCT 2025 |
| CITY | SAM GOV | OCT 2025 |
| NAME | SAM GOV | OCT 2025 |
| REGISTRATION EXPIRATION | SAM GOV | OCT 2025 |
| STATE | SAM GOV | OCT 2025 |
| WEBSITE | SAM GOV | OCT 2025 |
Status is computed from independent sources; nothing here is self-reported unless marked Claimed.